Galantamine for Cognitive Deficits in Schizophrenia
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the acute effects of the nicotinic receptor
allosteric modulator galantamine (0, 4 and 8 mg) on neurocognitive function in schizophrenic
smokers (n=20) versus schizophrenic nonsmokers (n=10) in an outpatient human laboratory
setting.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Yale University
Collaborator:
National Alliance for Research on Schizophrenia and Depression